AJSM - 2026-06-18 - Journal Article
Intraoperative Zoledronic Acid for Arthroscopic Rotator Cuff Repair Results in Distinct Circulating Micro-RNA Profiles Indicating Improved Tendon-to-Bone Healing.
Schanda JE, Hackl M, Bischl R, Ullrich R, Boesmueller S, Mittermayr R, Redl H, Grillari J, Fialka C
Topics
Key Takeaway
Intraoperative single-dose zoledronic acid produced distinct circulating miRNA profiles at 2 days post-repair—including significantly lower miR-140-3p in the treatment group and preserved miR-29a-3p, miR-21-5p, miR-192-5p, and miR-146a-5p versus controls—suggesting reduced enthesis inflammation/fibrosis and enhanced collagen synthesis as the molecular mechanism behind previously observed retear reduction.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This mechanistic substudy of a triple-blinded phase II RCT (NCT05677152) investigated whether intraoperative single-dose zoledronic acid alters circulating miRNA profiles in non-osteoporotic patients undergoing arthroscopic rotator cuff repair. Small RNA sequencing identified six miRNAs validated by RT-qPCR; at 2 days postoperatively, the zoledronic acid group showed significantly lower miR-140-3p (P=.047), while the control group showed significantly lower miR-29a-3p (P<.001), miR-21-5p (P=.036), miR-192-5p (P=.034), and miR-146a-5p (P<.001). Gene target analysis linked these differentially expressed miRNAs to COL1A1, COL3A1, VEGF, IGF-1, and TGF-β1, implicating pathways of collagen synthesis, vascularization, and anti-fibrotic/anti-inflammatory signaling.
Key Limitation
No structural healing outcome (MRI-confirmed retear rate) was reported within this substudy, so the observed miRNA differences cannot be directly correlated with actual tendon integrity at any time point.
Original Abstract
BACKGROUND
A prospective, randomized, placebo-controlled trial showed reduced retears after arthroscopic rotator cuff (RC) repair in patients without osteoporosis by a systemic single-dose of zoledronic acid. Distinct micro-ribonucleic acids (miRNAs) related to inflammation, fibrosis, and tendon-to-bone healing are associated with RC injuries.
PURPOSE
To investigate the longitudinal effects of a single-dose of zoledronic acid in patients without osteoporosis undergoing arthroscopic RC repair on circulating miRNAs in order to explore the molecular mechanism of this treatment.
STUDY DESIGN
Controlled laboratory study.
METHODS
Data were collected in the course of a single-center, prospective, randomized, placebo-controlled, triple-blinded (investigator, surgeon, patient) phase II trial. A total of 80 patients underwent arthroscopic RC repair and were intraoperatively randomized to the zoledronic acid group (n = 40) or the control group (n = 40). Circulating plasma miRNAs were assessed preoperatively, 2 days postoperatively, and 3 months postoperatively using small RNA sequencing and reverse transcription quantitative polymerase chain reaction (RT-qPCR).
RESULTS
Six miRNAs were selected for validation by RT-qPCR based on small RNA-sequencing analysis. No statistical differences in miRNA plasma levels were observed preoperatively between the 2 study groups. Two days after surgery, plasma levels were significantly lower for miR-140-3p ( P = .047) in the zoledronic acid group. In the control group, plasma levels were significantly lower for miR-29a-3p ( P < .001), miR-21-5p ( P = .036), miR-192-5p ( P = .034), and miR-146a-5p ( P < .001) 2 days after surgery. Three months after surgery, miRNA plasma levels of the 2 study groups equalized without any significant differences. Gene target analysis identified collagen type I alpha 1 chain, collagen type III alpha 1 chain, vascular endothelial growth factor, insulin-like growth factor 1, and transforming growth factor-β1 as targets of miRNAs impacted by zoledronic acid.
CONCLUSION
Longitudinal plasma miRNA expressions suggest a molecular response to zoledronic acid, potentially indicating a reduction of inflammation and fibrosis at the enthesis as well as increased collagen synthesis and vascularization, possibly explaining improved tendon-to-bone healing.
CLINICAL RELEVANCE
Zoledronic acid is a safe and easy-to-apply augmentation technique for patients undergoing arthroscopic RC repair.
REGISTRATION
NCT05677152 (ClinicalTrials.gov identifier).